Fibrin Gamma Peptide Blocks Microglia Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for degenerative neuronal disorders like multiple sclerosis (MS) fail to effectively inhibit microglia activation, which contributes to inflammatory demyelination and tissue damage, due to limitations in targeting the fibrin/Mac-1 interaction without affecting blood coagulation.
Innovation Solution
A peptide comprising 19 amino acids, specifically the fibrin gamma 377-395 peptide (YSMKKTTMKIIPFNRLTIG), is administered to block microglia activation by targeting the fibrin/Mac-1 interaction, thereby reducing inflammatory demyelination without interfering with blood coagulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anticoagulants are used to deplete fibrinogen, then microglia activation is inhibited, but hemorrhagic side effects occur
Solution Approach 1:
The patent segments the fibrinogen molecule by using a peptide antibody that specifically binds to only one of its functional sites (the microglia activation site) while leaving other sites (blood coagulation sites) untouched. This selective binding approach allows inhibition of microglia activation without affecting blood coagulation functions.
Solution Approach 2:
The peptide antibody exhibits local specificity by targeting a particular region of the fibrinogen molecule that is responsible for microglia activation. This localized action allows the therapeutic agent to address only the pathological function (microglia activation) while preserving other essential functions (blood coagulation) of the same molecule.
2Object-affected harmful factors
If fibrinogen is depleted to treat MS, then inflammatory demyelination is reduced, but blood coagulation is affected
Solution Approach 1:
The patent extracts or isolates the specific functional site on fibrinogen that mediates microglia activation. By using a peptide antibody that binds specifically to this extracted functional region, the therapy can target and inhibit only the inflammatory demyelination pathway without disrupting the overall fibrinogen molecule's blood coagulation function.
Solution Approach 2:
The peptide antibody serves as an intermediary that selectively binds to fibrinogen at the microglia activation site. This intermediary approach allows indirect inhibition of microglia activation through specific binding, while the unfettered portions of fibrinogen continue to perform blood coagulation functions normally.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively inhibits microglia activation and reduces clinical symptoms and disease pathogenesis in MS models, improving motor function and survival rates without affecting blood coagulation properties.
Implementation Method 1
A peptide comprising 19 amino acids, specifically the fibrin gamma 377-395 peptide (YSMKKTTMKIIPFNRLTIG), is administered to block microglia activation by targeting the fibrin/Mac-1 interaction
Data Source
AI summary
The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.